Coram Healthcare Introduces Hemophilia Services Division; Company Establishes New Focus on Providing Quality Care and Services to Patients with Hemophilia.

DENVER--(BUSINESS WIRE)--Nov. 4, 1999--

Coram Healthcare (NYSE:CRH), a leading national provider of alternate site infusion therapies, today announced that it has introduced a new division, Coram Hemophilia Services, designed to support existing and future patients with hemophilia.

Coram Hemophilia Services, headquartered in Malvern, Pa., offers patients a broad range of products and services including the provision of oral medications, clinical monitoring, home nursing, case management, billing and reimbursement, patient education programs and delivery of hemophilia factor. In addition, Coram Hemophilia Services will provide several lifestyle services for patients with hemophilia such as a comprehensive clinical pathway to assist patients who are undergoing joint replacement and other orthopedic procedures as well as information on fertility options for HIV discordant couples.

Coram has been servicing patients with hemophilia and other bleeding disorders for more than 15 years. The Company has created several new management positions to head Coram Hemophilia Services. Among those appointed are: Eric Hill, vice president, hemophilia services; David Madeiros, director, program development; Larry Madeiros, director, patient advocacy; Jim Lane, director of sales; and Joanne Boyer, director of operations.

"It is Coram's clinical specialty programs that have enabled us to differentiate ourselves and demonstrate to customers and patients our ability to provide quality care focused on specific disease states. The introduction of Coram Hemophilia Services was designed to place greater emphasis on hemophilia patients and cater to their specific needs and lifestyles. We identified an opportunity in the marketplace and saw a need to service these patients with dedicated, quality care and services. Moreover, we determined that these patients could also benefit from certain lifestyle services that would empower them to lead independent and active lifestyles. Our ability to continue this focus and extend our expertise into the hemophilia area will provide payers and patients alike with enhanced products, services and care," said Joseph Smith, Coram's chief operating officer.

"We have assembled an experienced management team to head our new hemophilia division. The new senior management team brings over 130 years of combined, first-hand hemophilia disease management knowledge and expertise to Coram's new division. In addition, the Madeiros brothers, who have hemophilia, are devoted to creating a hemophilia services division for Coram that fosters individually oriented client services and quality care. We look forward to the contributions they will make to this division and to our organization," concluded Smith.

Denver-based Coram Healthcare is a leading provider of high-quality home infusion therapy operating from approximately 88 locations in 44 states and Ontario, Canada. Coram Prescription Services (CPS) provides pharmacy benefit management services as well as mail order prescription drugs for chronically ill patients. The Clinical Research and Medical Informatics Division provides home care and product development services to pharmaceutical, biotechnology and medical device companies sponsoring clinical trials. These include specialized alternate site services such as drug administration, education, patient assessments, study coordination and data collection.

For more information, please visit the Company's web site at www.coramhealthcare.com.

This release, except for historical information, contains certain "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995) and information relating to Coram that are based on the beliefs of management of Coram as well as assumptions made by and information currently available to the management of Coram. The Company's actual results may vary materially from the forward-looking statements made in this report due to important factors such as: history of operating losses and uncertainties associated with future operating results; significant outstanding indebtedness; equity conversion rights held by existing debt holders; limited liquidity; reimbursement-related risks; shifts in the mix of parties that pay for the Company's services; dependence on relationships with third parties; uncertain future liabilities under capitation arrangements; concentration of large payers; industry and competition; timing of or ability to complete acquisitions; government regulation of the home healthcare industry; certain legal proceedings; dependence on key personnel; recruitment and retention of trained personnel; potential volatility of stock price; New York Stock Exchange listing status; and unanticipated impacts from the Year 2000 issue. See Item 7 - "Management's Discussion and Analysis of Financial Condition and Results of Operations - Risk Factors" in the Company's Annual Report on Form 10-K, as amended, for the year ended December 31, 1998. When used in this report, the words "estimate," "project", "believe," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. Such statements reflect the current views of Coram with respect to future events based on currently available information and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Coram does not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.